SCHEMBL14403201

SCHEMBL14403201

Cc1cc(NCCc2cc(C)[nH]c(=O)c2)nc(-c2cc(F)c(F)cc2F)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 5/20 0.51
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 2/20 0.38
ABL1 P00519 1/20 0.36
RIN1 Q13671 1/20 0.36
MAPT P10636 3/20 0.34
KDM4E B2RXH2 2/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
ALOX15 P16050 1/20 0.34
CASP1 P29466 1/20 0.34
HTT P42858 1/20 0.34
ATM Q13315 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
POLB P06746 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL392408 0.89 CYP1A2 (0.54) CYP1A2MEN1KMT2AALDH1A1HPGD
SCHEMBL389964 0.82 CYP1A2 (0.52) CYP1A2MEN1KMT2AALDH1A1HPGD
SCHEMBL8377531 0.75 CYP1A2 (0.56) CYP1A2MEN1KMT2AALDH1A1HPGD
SCHEMBL391954 0.74 CYP1A2 (0.85) CYP1A2MEN1KMT2AALDH1A1HPGD
SCHEMBL3691975 0.73 CYP1A2 (0.50) CYP1A2MEN1KMT2AALDH1A1HPGD
SCHEMBL391957 0.67 CYP1A2 (0.38) CYP1A2MEN1KMT2AALDH1A1HPGD
SCHEMBL391847 0.67 CYP1A2 (0.40) CYP1A2MEN1KMT2AALDH1A1HPGD
SCHEMBL1904848 0.67 CYP1A2 (0.36) CYP1A2MEN1KMT2AALDH1A1HPGD
SCHEMBL1905804 0.65 CYP1A2 (0.37) CYP1A2MEN1KMT2AALDH1A1HPGD
SCHEMBL390010 0.65 CYP1A2 (0.53) CYP1A2ABL1RIN1GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007120702-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO ARENA PHARMACEUTICALS, INC. (US) 2007-10-25 WO disclosed